OBJECTIVES: Brentuximab vedotin (BV), a CD30-directed antibody-drug conjugate, is approved for the treatment of adult patients with relapsed or refractory (RR) CD30+ Hodgkin Lymphoma (HL) following autologous stem cell transplant (ASCT) or following at least two prior therapies in HL patients who are not ASCT candidates. A systematic review was conducted to identify studies investigating treatments for adult RR HL patients who had relapsed post-ASCT with a particular interest in long-term survival. METHODS: Searches of electronic databases were performed in MEDLINE^® and MEDLINE^® in process, EMBASE, the Cochrane Central Register of Controlled Trials and PubMed (1946 – June 2015). Select conferences were screened. There were no restrictions by treatment. All study designs, except study protocols, were considered. Studies with ≥10 RR HL patients were included. Treatment outcomes (overall response rate, progression-free survival and overall survival) were reviewed. RESULTS: Eighty studies were identified for inclusion. The most commonly reported treatments were either pharmacological or allogeneic SCT with reduced intensity conditioning, corresponding with current treatment guidelines. Ten studies reported overall survival (OS) at five years. In patients who received allogeneic SCT, five year OS ranged from 20-42% in three studies and RR HL patient numbers ranged from 20-38. There was one outlier study (N=38) in which five year OS was noticeably higher (65%); however, OS in this study was from time of initial ASCT, not from time of allogeneic SCT. The only five year OS reported for patients receiving specified drug treatments was 35% (N=47); median age of these patients was 25 years. CONCLUSIONS: Few studies have reported long-term OS data for RR HL patients post-ASCT. From the available evidence, allogeneic SCT appears to provide the greatest OS benefit. Subsequently, the pivotal BV study has published a five year OS estimate of 41%, comparable to the higher range of reported five year OS for allogeneic SCT.